Synthon, Perrigo gain US FDA nod for generic allergy drug, winning first-to-file status
This article was originally published in Scrip
Executive Summary
Perrigo's shares got a slight 2.1% boost, or $1.80, on 18 May after its partner Synthon Pharmaceuticals won approval from the US FDA on their abbreviated new drug application (ANDA) for Levocetirizine solution, a generic version of UCB's Xyzal, a histamine H1-receptor antagonist indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and as a treatment for uncomplicated skin manifestations of chronic idiopathic urticaria.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.